Alt
/content/dam/asset-migration/headshots/uk-doctor-headshots/UK_oncology_headshot_dr_muthiah_sivaramalingam.jpg

Dr Muthiah Sivaramalingam

Dr Muthiah Sivaramalingam
Muthiah
Sivaramalingam
MBBS, MRCP, FRCR Clinical Oncologist

Languages spoken

English

Expert in

Breast, gastrointestinal,  genitourinary, head and neck, lung and prostate cancer

Overview

Centres

Birmingham
Birmingham

Little Aston Hall Drive, Sutton Coldfield, B74 3BF

52.60208, -1.87412
/uk/our-centres/birmingham
+44 (0) 121 353 3055
mediahawkNumber3664 mhMobile

Specialises in

Breast Cancer
Condition
Condition/Cancer
Condition/Cancer/Breast cancer
Gastrointestinal cancer
Condition
Condition/Cancer
Condition/Cancer/Gastrointestinal cancer
Genitourinary cancer
Condition
Condition/Cancer
Condition/Cancer/Genitourinary cancer
Head and neck cancer
Condition
Condition/Cancer
Condition/Cancer/Head and neck cancer
Lung cancer
Condition
Condition/Cancer
Condition/Cancer/Lung cancer
Prostate cancer
Condition
Condition/Cancer
Condition/Cancer/Prostate cancer

Treatments

Chemotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Chemotherapy
Colposcopy
Service
Service/Cancer
Service/Cancer/Pathology tests and procedures
Service/Cancer/Pathology tests and procedures/Colposcopy
Core biopsy
Service
Service/Cancer
Service/Cancer/Pathology tests and procedures
Service/Cancer/Pathology tests and procedures/Core biopsy
Cystoscopy
Service
Service/Cancer
Service/Cancer/Pathology tests and procedures
Service/Cancer/Pathology tests and procedures/Cystoscopy
CT scanning
Service
Service/Cancer
Service/Cancer/Imaging scans
Service/Cancer/Imaging scans/CT
Deep Inspiration Breath Hold (DIBH)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Deep inspiration breath hold
External beam radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/External beam radiotherapy
Gamma Knife
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Gamma Knife
Haematology
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Haematology
Image guided radiotherapy (IGRT)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Image-guided radiotherapy
Immunotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Immunotherapy
Intensity modulated radiotherapy (IMRT)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Intensity modulated radiotherapy
Mammography
Service
Service/Cancer
Service/Cancer/Imaging scans
Service/Cancer/Imaging scans/Mammogram
PET/CT scan
Service
Service/Cancer
Service/Cancer/Imaging scans
Service/Cancer/Imaging scans/PET CT
Radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Radiotherapy
SpaceOAR ®
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Prostate cancer spacers
Stereotactic ablative radiotherapy (SABR)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Stereotactic ablative radiotherapy (SABR)
Surface guided radiotherapy (SGRT)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Surface-guided radiotherapy

Dr Muthiah Sivaramalingam has been a Consultant Clinical Oncologist in the United Kingdom for over 13 years. He has been involved in the treatment of patients with different types of cancers with an ever-evolving array of therapeutic modalities in a rapidly changing and exciting field of clinical oncology over the last decade. Dr Sivaramalingam has been involved in the forefront of developments such as IMRT, IGRT and SABR. Unique to the practice in the United Kingdom, as a Clinical Oncologist, he is also experienced in the use of various forms of systemic therapies for treatment of solid tumours including biological agents, targeted agents and more recently immunotherapy in various combinations in this specialty. Dr Muthiah Sivaramalingam is evolved as a leader in a multidisciplinary (MDT) environment. He chaired the weekly Head and Neck cancer Multidisciplinary team (MDT). Dr Sivaramalingam was the lead for Head and Neck Oncology and Tumour site-specific lead for Neuroendocrine Tumour (NET) and Gastrointestinal Tumour (GIST). He was the clinical lead for implementation of IMRT (in 2010) and SABR (2017) in Preston.

I am involved in the implementation of SABR at UHNM currently. I strongly believe in clinical research being the way forward for our future progress in oncology and the self-assessment process of regular auditing aspects of our practice as the cornerstone in providing the best possible care for our patients. 

Expertise and interests

Interests

  • IMRT
  • Immunotherapy
  • Modern Radiotherapeutic techniques and innovations
  • Specialism in treatment of Lung cancers, Gastrointestinal cancers, Head and Neck Cancers, NET and GIST
  • Expertise in Chemotherapy, Biologic therapy
  • IGRT and other forms of conformal Radiotherapy

Professional association

  • Royal College of Radiologists
  • ASTRO

Accomplishments

Awards

  • BTOG Poster Prize (Chemotherapy for NSCLC: One of top 10 prizes from over a hundred selected Posters) (Dublin, Ireland) 2009
  • Clinical Excellence Awards [Level 2 (Local)] 2011

Publications

  • Post mastectomy radiotherapy: the British Columbia trial. Advances in Breast Cancer; Vol 2, Issue 2, June 2005, P27-29: Peter A Canney and Muthu Siva.
  • Small cell neuroendocrine carcinoma of uterine cervix - The Scottish experience. Journal of Clinical Oncology 2006; Vol 24, No 18S Part 1, 652s: Siva M, Mahmood R, Kakumanu S, Sadozye A, Reed N.
  • Adjuvant treatment for adenocarcinoma of stomach and oesophago-gastric junction - A Glasgow experience. Annals of Oncology; Vol 17, Supplement 6, vi98, June 2006: Sivaramalingam M, MacLaren V, and Yosef H.
  • Adjuvant Treatment of Gastric and Oesophago-gastric Junction Adenocarcinoma – a Glasgow Experience. Clinical Oncology; Vol 19 (2007) Supplement 1, S46: M. Sivaramalingam, A. Shaukat, V. MacLaren, and H. Yosef.
  • Capecitabine in advanced breast cancer: Predictive factors for response. J Clin Oncol 26; 2008 (May 20 Suppl): M Siva et al.